

July 26, 2024

Shinichiro Haga  
Lead Executive Officer and Senior General Manager, Corporate Strategy  
Asahi Kasei Corporation  
1-1-2 Yurakucho, Chiyoda-ku  
Tokyo, Japan 100-0006

Re: Asahi Kasei Corporation  
Calliditas Therapeutics AB  
Schedule TO-T filed July 18, 2024 by Asahi Kasei Corporation  
File No. 005-91523

Dear Shinichiro Haga:

We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to these comments by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response.

After reviewing your response to these comments, we may have additional comments.

Schedule TO-T filed July 18, 2024  
General

1. We note your disclosure in Item 7 of the Schedule TO that [t]he Offer to Purchase is not subject to a financing condition. In this respect, Item 7 of Schedule TO and Item 1007(b) of Regulation M-A require disclosure of material conditions, if any, to any financing of consideration to be provided in an offer, as opposed to disclosure regarding conditions to the consummation of an offer. Please revise accordingly.
2. In your response letter, describe the facts supporting Buyer's reliance on Rule 14d-1(d) in connection with the Offers, including the level of U.S. ownership in the Company and as of what date it was calculated.
3. In multiple places in the Offer to Purchase, including on pages 6, 10 and 11, you reserve the right to complete the Offers at a lower acceptance level than the current minimum of 90%. Please indicate in your response letter whether you intend to rely on the guidance provided in Section II.C.5 of SEC Release No. 34-58597 (September 19, 2008) in order to  
July 26, 2024  
Page 2

lower the minimum acceptance condition in the Offers without extending them. If so, please confirm in your response letter and describe in the offer materials how you will comply with all of the conditions to this guidance.  
Summary Term Sheet, page 1

4. On page 9 of the Offer to Purchase, you state that Buyer and its affiliates and brokers may make certain purchases of Offer Securities outside of the United States before, during or after the Offer Period to the extent permissible under Rule 14e-5 of the Exchange Act, in accordance with Rule 14e-5(b)(12). In your response letter, please outline the facts that you believe support your reliance on the exception in Rule 14e-5(b)(12).
5. See our last comment above and the reference to Rule 14e-5 on page ii of the offer materials. We further note the reference there to your plans to "consider or explore one or more corporate transactions involving the Company outside the United States." Please revise to explain, where appropriate in the offer materials, what corporate transactions you

are referring to here and how they may affect the Offers and the Company.  
Withdrawal Rights, page 21

6. Please disclose the date after which securityholders may withdraw securities tendered in the U.S. Offer pursuant to U.S. federal law. See Item 1004(a)(1)(vi) of Regulation M-A and Section 14(d)(5) of the Exchange Act.

7. Refer to your disclosure on page 21 that [a]ll questions as to the form and validity (including time of receipt) of any notice of withdrawal will be determined by Buyer, in its sole discretion, whose determination will be final and binding upon the tendering party.

Please revise to remove the implication that securityholders may not challenge such determinations in a court of competent jurisdiction.

Source and Amount of Funds, page 27

8. We note your disclosure that Buyer may consummate the Offers and the Compulsory

Redemption using cash on hand and may also draw down upon Buyer's existing debt

facilities. Specify the portion of funds that are expected to come from such debt

facilities. In addition, disclose the parties to the facilities, the applicable interest rates and

any other material terms of the arrangements. Refer to Item 1007(d) of Regulation M-A.

Conditions to the Offers, page 33

9. Refer to your disclosure on page 33 that [t]he failure by Buyer at any time to exercise

any of the foregoing rights will not be deemed a waiver of any such right, and each such

right will be deemed an ongoing right which may be asserted at any time and from time to

time. If an Offer Condition is triggered while the Offers are pending, in our view,

Buyer must promptly inform securityholders whether Buyer will assert the condition and

terminate the Offers, or waive it and continue. Reserving the right to waive a condition at

any time and from time to time is inconsistent with your obligation in this regard. Please

revise your disclosure, consistent with the views expressed here.

We remind you that the filing persons are responsible for the accuracy and adequacy of

their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

July 26, 2024

Page 3

Please direct any questions to Blake Grady at 202-551-8573.

Sincerely,

Division of

Corporation Finance

Office of Mergers &

Acquisitions